Boehringer Ingelheim (BI) has done a full 180-degree turn on patient involvement in trial design in recent years, moving from virtually no patient input to incorporating patient feedback in nearly all of its protocols today. The German pharma giant elaborated on how it accomplished this during a session at the 2024 Summit for Clinical Ops Executives (SCOPE).